Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes.
anti‐infective agent
infections
myelodysplastic syndromes
population‐based
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
13
01
2022
revised:
09
03
2022
accepted:
09
03
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
epublish
Résumé
The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This study examines prescription rates of anti-infective agents in MDS patients before and after diagnosis, in both in- and outpatient settings, to provide information on infection management in clinical practice. We performed a population-based study using the HemoBase registry, containing data of all MDS patients diagnosed since 2005 in Friesland, the Netherlands. Community and hospital pharmacies provided prescription data from 1995 to 2020. Data were obtained for 203 of 292 patients (70%). Patients received significantly more anti-infective agents, predominantly antibacterials (70%), after diagnosis compared to before: 148.7 defined daily dose/1000 days (DID) (95% CI: 146.9-150.5) and 55.1 DID (95% CI: 54.5-55.8,
Identifiants
pubmed: 36051088
doi: 10.1002/jha2.422
pii: JHA2422
pmc: PMC9422012
doi:
Types de publication
Journal Article
Langues
eng
Pagination
775-784Informations de copyright
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Eur J Cancer. 2017 Nov;86:178-185
pubmed: 28992561
Eur J Haematol. 2019 Jul;103(1):56-63
pubmed: 31058390
J Clin Oncol. 2020 May 20;38(15):1723-1735
pubmed: 32058844
Clin Infect Dis. 2015 May 1;60(9):1308-16
pubmed: 25747410
Dtsch Arztebl Int. 2020 Oct 9;117(41):679-686
pubmed: 33357337
Haematologica. 2012 Oct;97(10):1459-70
pubmed: 22733024
Am J Hematol. 2020 Jul;95(7):792-798
pubmed: 32242967
Mediterr J Hematol Infect Dis. 2018 Jul 01;10(1):e2018039
pubmed: 30002795
J Antimicrob Chemother. 2011 Jul;66(7):1609-16
pubmed: 21596722
Blood Adv. 2021 Mar 9;5(5):1344-1351
pubmed: 33656535
Eur J Haematol. 2017 Aug;99(2):112-118
pubmed: 28321924
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Mayo Clin Proc. 2019 Aug;94(8):1467-1474
pubmed: 31378228
Ann Hematol. 2016 May;95(6):937-44
pubmed: 27025507
Int J Environ Res Public Health. 2020 Dec 21;17(24):
pubmed: 33371225
Am J Hematol. 2013 Feb;88(2):130-4
pubmed: 23345248
Cancer Med. 2017 Dec;6(12):2814-2821
pubmed: 29058375
Clin Interv Aging. 2018 Apr 17;13:657-667
pubmed: 29713150
Clin Lymphoma Myeloma Leuk. 2019 May;19(5):264-274.e4
pubmed: 30898482
BMC Infect Dis. 2019 Jan 24;19(1):84
pubmed: 30678645
Blood Transfus. 2022 Jan;20(1):18-26
pubmed: 33370223
Ann Clin Microbiol Antimicrob. 2020 Feb 17;19(1):7
pubmed: 32066448
Expert Rev Hematol. 2016 Jun;9(6):607-14
pubmed: 27100058
Leuk Res. 2011 Apr;35(4):499-503
pubmed: 20674021
Haematologica. 2022 Mar 01;107(3):655-667
pubmed: 33567812
Ann Hematol. 2017 Nov;96(11):1833-1840
pubmed: 28803258
Transfusion. 2021 Oct;61(10):2877-2884
pubmed: 34480360
J Clin Oncol. 2010 Jun 10;28(17):2847-52
pubmed: 20421543
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Cancer. 2010 May 1;116(9):2174-9
pubmed: 20162709
J Immunol. 2020 Apr 15;204(8):2098-2109
pubmed: 32179638
Int J Environ Res Public Health. 2020 May 06;17(9):
pubmed: 32384740
Hematol Oncol. 2020 Apr;38(2):189-196
pubmed: 31891213
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6
pubmed: 24220615
Med Mal Infect. 2015 Aug;45(8):313-7
pubmed: 26112930
Leuk Res. 2020 Sep;96:106419
pubmed: 32683127
Cancer. 2014 Jun 1;120(11):1686-94
pubmed: 24643720
Blood Rev. 2019 Mar;34:16-25
pubmed: 30448050
Transpl Infect Dis. 2013 Dec;15(6):652-7
pubmed: 24010918
Eur J Cancer. 2014 Mar;50(5):1004-12
pubmed: 24388662